Author | Kristi Rosa | OncLive

Author | Kristi Rosa


FDA Approval Sought for Pralsetinib in Advanced RET+ Thyroid Cancers

July 02, 2020


A new drug application has been submitted to the FDA for pralsetinib (BLU-667) for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancers.

Frontline NALIRIFOX Regimen Shows Promising Activity, Tolerability in Pancreatic Cancer

July 01, 2020


The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

FDA Approves Avelumab as Frontline Maintenance in Metastatic Urothelial Carcinoma

July 01, 2020


The FDA has approved avelumab (Bavencio) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy.

Pivotal Phase 3 CONTACT-02 Trial of Cabozantinib/Atezolizumab in mCRPC Initiated

June 30, 2020


Exelixis, Inc. has launched the phase 3 CONTACT-02 trial examining cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer who have received prior treatment with 1 novel hormonal therapy.